Table 1.

Outcomes after anticoagulation-related gastrointestinal tract bleeding in patients who do and do not resume anticoagulation therapy

StudyIndication for anticoagulationAnticoagulantFollow-up periodAdjusted HR-TE (95% CI)Adjusted HR-recurrent GIB (95% CI)Adjusted HR all-cause mortality (95% CI)
Witt 2012, N = 4426  AF, VTE, MVR, Other Warfarin 90 d 0.05 (0.01-0.58) 1.32 (0.50-3.57) 0.31 (0.15-0.62) 
Qureshi 2014, N = 13295  AF Warfarin 1-y (TE) 90-d (GIB) 0.71 (0.54-0.93) 1.18 (0.94-1.10) 0.67 (0.56-0.81) 
2-y (ACM) 
Staerk 2015, N = 34097  AF Single OAC* 5-y 0.41 (0.31-0.54) 1.22 (0.84-1.77) 0.39 (0.34-0.46) 
Single antiplatelet† 0.76 (0.61-0.95) 1.19 (0.82-1.74) 0.76 (0.68-0.86) 
OAC + antiplatelet* 0.54 (0.36-0.82) 1.34 (0.79-2.28) 0.41 (0.32-0.52) 
Dual antiplatelet‡ 0.79 (0.34-1.84) 0.58 (0.08-4.30) 0.88 (0.57-1.36) 
Sengupta 2015, N = 1978  Various Warfarin 90 d 0.12 (0.006-0.81) 2.17 (0.86-6.67) 0.63 (0.22-1.89) 
StudyIndication for anticoagulationAnticoagulantFollow-up periodAdjusted HR-TE (95% CI)Adjusted HR-recurrent GIB (95% CI)Adjusted HR all-cause mortality (95% CI)
Witt 2012, N = 4426  AF, VTE, MVR, Other Warfarin 90 d 0.05 (0.01-0.58) 1.32 (0.50-3.57) 0.31 (0.15-0.62) 
Qureshi 2014, N = 13295  AF Warfarin 1-y (TE) 90-d (GIB) 0.71 (0.54-0.93) 1.18 (0.94-1.10) 0.67 (0.56-0.81) 
2-y (ACM) 
Staerk 2015, N = 34097  AF Single OAC* 5-y 0.41 (0.31-0.54) 1.22 (0.84-1.77) 0.39 (0.34-0.46) 
Single antiplatelet† 0.76 (0.61-0.95) 1.19 (0.82-1.74) 0.76 (0.68-0.86) 
OAC + antiplatelet* 0.54 (0.36-0.82) 1.34 (0.79-2.28) 0.41 (0.32-0.52) 
Dual antiplatelet‡ 0.79 (0.34-1.84) 0.58 (0.08-4.30) 0.88 (0.57-1.36) 
Sengupta 2015, N = 1978  Various Warfarin 90 d 0.12 (0.006-0.81) 2.17 (0.86-6.67) 0.63 (0.22-1.89) 

ACM, all-cause mortality; AF, atrial fibrillation; HR, hazard ratio; MVR, mechanical valve replacement; TE, thromboembolism; VTE, venous thromboembolism.

*

Mainly Vitamin K antagonists.

†

Aspirin or P2Y12 antagonists.

‡

Aspirin and P2Y12 antagonists.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal